Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
(Sapanisertib + serabelisib) by Faeth Therapeutics for Endometrial Cancer: Likelihood of Approval
(Sapanisertib + serabelisib) is under clinical development by Faeth Therapeutics and currently in Phase I for Endometrial Cancer. According to...
Data Insights
(Sapanisertib + serabelisib) by Faeth Therapeutics for Solid Tumor: Likelihood of Approval
(Sapanisertib + serabelisib) is under clinical development by Faeth Therapeutics and currently in Phase I for Solid Tumor. According to...